## Todd Lencz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1718362/publications.pdf

Version: 2024-02-01

7551 4978 31,908 222 77 citations h-index papers

g-index 259 259 259 31268 all docs docs citations times ranked citing authors

167

#	Article	IF	Citations
1	Biological insights from 108 schizophrenia-associated genetic loci. Nature, 2014, 511, 421-427.	13.7	6,934
2	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45, 984-994.	9.4	2,067
3	Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nature Genetics, 2018, 50, 1112-1121.	9.4	1,835
4	Genome-wide association study identifies five new schizophrenia loci. Nature Genetics, 2011, 43, 969-976.	9.4	1,758
5	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
6	Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nature Genetics, 2018, 50, 912-919.	9.4	893
7	Reduced Prefrontal Gray Matter Volume and Reduced Autonomic Activity in Antisocial Personality Disorder. Archives of General Psychiatry, 2000, 57, 119.	13.8	889
8	Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience, 2015, 18, 199-209.	7.1	701
9	Cognitive-perceptual, Interpersonal, and Disorganized Features of Schizotypal Personality. Schizophrenia Bulletin, 1994, 20, 191-201.	2.3	519
10	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	5 <b>.</b> 8	484
11	Quantitative magnetic resonance imaging in temporal lobe epilepsy: Relationship to neuropathology and neuropsychological function. Annals of Neurology, 1992, 31, 629-637.	2.8	401
12	Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19942-19947.	<b>3.</b> 3	367
13	Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia. Biological Psychiatry, 2006, 59, 863-871.	0.7	364
14	Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia. Archives of General Psychiatry, 2007, 64, 1115.	13.8	357
15	Orbital Frontal and Amygdala Volume Reductions in Obsessive-compulsive Disorder. Archives of General Psychiatry, 1999, 56, 913.	13.8	328
16	The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. Schizophrenia Bulletin, 2003, 29, 633-651.	2.3	327
17	Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia. JAMA Psychiatry, 2015, 72, 5.	6.0	277
18	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Science Translational Medicine, 2018, 10, .	5.8	273

#	Article	IF	CITATIONS
19	Volume Reduction in Prefrontal Gray Matter in Unsuccessful Criminal Psychopaths. Biological Psychiatry, 2005, 57, 1103-1108.	0.7	265
20	Antipsychotic drugs and obesity. Trends in Molecular Medicine, 2011, 17, 97-107.	3.5	256
21	Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Molecular Psychiatry, 2007, 12, 572-580.	4.1	255
22	Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Molecular Psychiatry, 2011, 16, 429-441.	4.1	250
23	Length Distributions of Identity by Descent Reveal Fine-Scale Demographic History. American Journal of Human Genetics, 2012, 91, 809-822.	2.6	240
24	Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. American Journal of Human Genetics, 2015, 96, 283-294.	2.6	225
25	Clinical and Neuropsychological Correlates of White Matter Abnormalities in Recent Onset Schizophrenia. Neuropsychopharmacology, 2008, 33, 976-984.	2.8	220
26	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 2004, 68, 37-48.	1.1	207
27	Risk Factors for Psychosis: Impaired Social and Role Functioning. Schizophrenia Bulletin, 2012, 38, 1247-1257.	2.3	206
28	Autonomic stress reactivity and executive functions in successful and unsuccessful criminal psychopaths from the community Journal of Abnormal Psychology, 2001, 110, 423-432.	2.0	205
29	Genomeâ€wide association study of schizophrenia in Ashkenazi Jews. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 649-659.	1.1	203
30	Corpus Callosum Abnormalities in Psychopathic Antisocial Individuals. Archives of General Psychiatry, 2003, 60, 1134.	13.8	202
31	D <sub>2</sub> Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. American Journal of Psychiatry, 2010, 167, 763-772.	4.0	192
32	Hippocampal structural asymmetry in unsuccessful psychopaths. Biological Psychiatry, 2004, 55, 185-191.	0.7	185
33	Can Antidepressants Be Used to Treat the Schizophrenia Prodrome?. Journal of Clinical Psychiatry, 2007, 68, 546-557.	1.1	185
34	Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT). Molecular Psychiatry, 2014, 19, 168-174.	4.1	178
35	Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. American Journal of Psychiatry, 2016, 173, 69-77.	4.0	168
36	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain. Archives of General Psychiatry, 2012, 69, 904.	13.8	165

#	Article	IF	CITATIONS
37	Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia Research, 2011, 126, 257-264.	1.1	162
38	Genetic variation in DTNBP1 influences general cognitive ability. Human Molecular Genetics, 2006, 15, 1563-1568.	1.4	160
39	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835.	5.8	156
40	Specificity in the correlation of verbal memory and hippocampal neuron loss: Dissociation of memory, language, and verbal intellectual ability. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1992, 14, 662-672.	1.4	152
41	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2016, 42, 1418-1437.	2.3	149
42	Smaller Anterior Hippocampal Formation Volume in Antipsychotic-Naive Patients With First-Episode Schizophrenia. American Journal of Psychiatry, 2003, 160, 2190-2197.	4.0	147
43	DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients. American Journal of Psychiatry, 2006, 163, 529-531.	4.0	146
44	The schizophrenia prodrome: treatment and high-risk perspectives. Schizophrenia Research, 2002, 54, 177-186.	1.1	132
45	Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophrenia Research, 1992, 7, 237-247.	1.1	131
46	Treatment of the schizophrenia prodrome: is it presently ethical?. Schizophrenia Research, 2001, 51, 31-38.	1.1	129
47	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. American Journal of Psychiatry, 2019, 176, 21-28.	4.0	127
48	Gray Matter Structural Alterations in Psychotropic Drug-Naive Pediatric Obsessive-Compulsive Disorder: An Optimized Voxel-Based Morphometry Study. American Journal of Psychiatry, 2008, 165, 1299-1307.	4.0	124
49	Candidate Gene Analysis Identifies a Polymorphism in <i>HLA-DQB1</i> Associated With Clozapine-Induced Agranulocytosis. Journal of Clinical Psychiatry, 2011, 72, 458-463.	1.1	124
50	Identification of Genetic Loci Jointly Influencing Schizophrenia Risk and the Cognitive Traits of Verbal-Numerical Reasoning, Reaction Time, and General Cognitive Function. JAMA Psychiatry, 2017, 74, 1065.	6.0	123
51	Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Reports Medicine, 2021, 2, 100288.	3.3	121
52	High rate of disease-related copy number variations in childhood onset schizophrenia. Molecular Psychiatry, 2014, 19, 568-572.	4.1	116
53	White Matter Abnormalities in Early-Onset Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 934-941.	0.3	115
54	COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behavioral and Brain Functions, 2005, 1, 19.	1.4	115

#	Article	IF	CITATIONS
55	Neurocognitive Profile in Adolescents with Early-Onset Schizophrenia: Clinical Correlates. Biological Psychiatry, 2005, 58, 705-712.	0.7	111
56	Lower Orbital Frontal White Matter Integrity in Adolescents With Bipolar I Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 79-86.	0.3	111
57	Runs of Homozygosity Implicate Autozygosity as a Schizophrenia Risk Factor. PLoS Genetics, 2012, 8, e1002656.	1.5	109
58	Early identification and high-risk strategies for bipolar disorder. Bipolar Disorders, 2007, 9, 324-338.	1.1	108
59	Cognitive Development in Schizophrenia: Follow-Back from the First Episode. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 270-282.	0.8	107
60	DISC1 and neurocognitive function in schizophrenia. NeuroReport, 2005, 16, 1399-1402.	0.6	105
61	Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets. Cell Reports, 2017, 21, 2597-2613.	2.9	103
62	DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophrenia Research, 2007, 89, 169-172.	1.1	102
63	Investigation of frontal lobe subregions in first-episode schizophrenia1This study was presented in part at the 1996 Meeting of the Society for Research in Psychopathology in Atlanta, GA, and the 1997 Meeting of the International Congress on Schizophrenia Research in Colorado Springs, CO.1.  Psychiatry Research - Neuroimaging, 1999, 90, 1-15.	0.9	101
64	Dysbindin Genotype and Negative Symptoms in Schizophrenia. American Journal of Psychiatry, 2006, 163, 532-534.	4.0	101
65	Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: Evidence of epistasis and competitive binding. Human Molecular Genetics, 2008, 17, 2462-2473.	1.4	101
66	Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nature Communications, 2013, 4, 2739.	5.8	101
67	Prefrontal white matter in pathological liars. British Journal of Psychiatry, 2005, 187, 320-325.	1.7	100
68	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia Bulletin, 2015, 41, 1227-1236.	2.3	100
69	Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophrenia Research, 2000, 43, 97-108.	1.1	94
70	An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Research - Neuroimaging, 1992, 45, 123-137.	0.9	93
71	Impairments in Perceptual Competency and Maintenance on a Visual Delayed Match-to-Sample Test in First-Episode Schizophrenia. Archives of General Psychiatry, 2003, 60, 238.	13.8	90
72	Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Molecular Psychiatry, 2015, 20, 820-826.	4.1	89

#	Article	IF	CITATIONS
73	DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biological Psychology, 2008, 79, 103-110.	1.1	88
74	A Schizophrenia Risk Gene, ZNF804A, Influences Neuroanatomical and Neurocognitive Phenotypes. Neuropsychopharmacology, 2010, 35, 2284-2291.	2.8	87
75	Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. American Journal of Human Genetics, 2019, 105, 334-350.	2.6	86
76	Reduced right hemisphere activation in severely abused violent offenders during a working memory task: An fMRI study. Aggressive Behavior, 2001, 27, 111-129.	1.5	83
77	Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. British Journal of Psychiatry, 2007, 190, 230-236.	1.7	82
78	Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. Schizophrenia Research, 2018, 202, 64-71.	1.1	82
79	Genome-wide Association Study of Maximum Habitual Alcohol Intake in >140,000 U.S. European and African American Veterans Yields Novel Risk Loci. Biological Psychiatry, 2019, 86, 365-376.	0.7	82
80	The Genetics of Symptom-Based Phenotypes: Toward a Molecular Classification of Schizophrenia. Schizophrenia Bulletin, 2008, 34, 1047-1053.	2.3	80
81	Screening Human Embryos for Polygenic Traits Has Limited Utility. Cell, 2019, 179, 1424-1435.e8.	13.5	78
82	Pharmacogenetics in psychiatry: translating research into clinical practice. Molecular Psychiatry, 2012, 17, 760-769.	4.1	76
83	Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia. Biological Psychiatry, 2007, 61, 1208-1210.	0.7	73
84	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. Journal of Psychiatric Research, 2016, 81, 95-101.	1.5	70
85	Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders. Translational Psychiatry, 2019, 9, 300.	2.4	70
86	Implication of a Rare Deletion at Distal 16p11.2 in Schizophrenia. JAMA Psychiatry, 2013, 70, 253.	6.0	69
87	DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and Genomics, 2010, 20, 569-572.	0.7	68
88	The Assessment of "Prodromal Schizophrenia": Unresolved Issues and Future Directions. Schizophrenia Bulletin, 2003, 29, 717-728.	2.3	67
89	GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Molecular Psychiatry, 2011, 16, 1117-1129.	4.1	67
90	In Vivo MicroRNA Detection and Quantitation in Cerebrospinal Fluid. Journal of Molecular Neuroscience, 2012, 47, 243-248.	1.1	64

#	Article	IF	Citations
91	Association of a Schizophrenia Risk Variant at the <i>DRD2 </i> li>Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia Bulletin, 2015, 41, 1248-1255.	2.3	64
92	Cannabis use disorders in schizophrenia: Effects on cognition and symptoms. Schizophrenia Research, 2010, 120, 95-100.	1.1	62
93	Subgenual cingulate cortical activity predicts the efficacy of electroconvulsive therapy. Translational Psychiatry, 2016, 6, e789-e789.	2.4	62
94	Genome-wide autozygosity is associated with lower general cognitive ability. Molecular Psychiatry, 2016, 21, 837-843.	4.1	62
95	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	0.7	61
96	Convergent Findings for Abnormalities of the NF-κB Signaling Pathway in Schizophrenia. Neuropsychopharmacology, 2013, 38, 533-539.	2.8	59
97	Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophrenia Research, 2013, 146, 285-288.	1.1	58
98	Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia. Neuropsychopharmacology, 2017, 42, 2214-2221.	2.8	55
99	Gray matter structural alterations in obsessive–compulsive disorder: Relationship to neuropsychological functions. Psychiatry Research - Neuroimaging, 2008, 164, 123-131.	0.9	53
100	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology, 2015, 44, 1706-1721.	0.9	53
101	Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophrenia Research, 2009, 107, 262-266.	1.1	52
102	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Gastroenterology, 2016, 151, 710-723.e2.	0.6	51
103	Predictors of Remission, Schizophrenia, and Bipolar Disorder in Adolescents with Brief Psychotic Disorder or Psychotic Disorder Not Otherwise Specified Considered At Very High Risk for Schizophrenia. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 475-490.	0.7	50
104	Pharmacogenetics of antipsychotic-induced side effects. Dialogues in Clinical Neuroscience, 2009, 11, 405-415.	1.8	50
105	Russell's adaptation of the Wechsler Memory Scale as an index of hippocampal pathology. Journal of Epilepsy, 1992, 5, 24-30.	0.4	49
106	Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. Human Molecular Genetics, 2014, 23, 4693-4702.	1.4	49
107	Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. Genome Biology, 2012, 13, R2.	13.9	48
108	Genomics and the future of pharmacotherapy in psychiatry. International Review of Psychiatry, 2007, 19, 523-530.	1.4	47

#	Article	IF	CITATIONS
109	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2015, 41, 1237-1247.	2.3	45
110	Novel multi-nucleotide polymorphisms in the human genome characterized by whole genome and exome sequencing. Nucleic Acids Research, 2010, 38, 6102-6111.	6.5	44
111	The Relationship of Common Risk Variants and Polygenic Risk for Schizophrenia to Sensorimotor Gating. Biological Psychiatry, 2016, 79, 988-996.	0.7	44
112	Meta-Analysis of Genetic Variation in DTNBP1 and General Cognitive Ability. Biological Psychiatry, 2010, 68, 1126-1133.	0.7	43
113	The CSMD1 genome-wide associated schizophrenia risk variant rs10503253 affects general cognitive ability and executive function in healthy males. Schizophrenia Research, 2014, 154, 42-47.	1.1	42
114	Brain morphometry using diffusion-weighted magnetic resonance imaging: application to schizophrenia. NeuroReport, 2005, 16, 1455-1459.	0.6	41
115	Localisation of increased prefrontal white matter in pathological liars. British Journal of Psychiatry, 2007, 190, 174-175.	1.7	41
116	Patterns of stress in schizophrenia. Psychiatry Research, 2008, 160, 38-46.	1.7	41
117	The serotonin transporter gene and disease modification in psychosis: Evidence for systematic differences in allelic directionality at the 5-HTTLPR locus. Schizophrenia Research, 2009, 111, 103-108.	1.1	40
118	Association of Genetic Variation in the <i><i>MET</i>Proto-Oncogene With Schizophrenia and General Cognitive Ability. American Journal of Psychiatry, 2010, 167, 436-443.</i>	4.0	40
119	Deficits in memory strategy use are related to verbal memory impairments in adolescents with schizophrenia-spectrum disorders. Schizophrenia Research, 2006, 85, 201-212.	1.1	39
120	The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan. Molecular Psychiatry, 2014, 19, 1125-1132.	4.1	39
121	The Variance of Identity-by-Descent Sharing in the Wright–Fisher Model. Genetics, 2013, 193, 911-928.	1.2	38
122	Increased height and bulk in antisocial personality disorder and its subtypes. Psychiatry Research, 2001, 105, 211-219.	1.7	37
123	Prefrontal Structural and Functional Deficits in Schizotypal Personality Disorder. Schizophrenia Bulletin, 2002, 28, 501-513.	2.3	36
124	Molecular differentiation of schizoaffective disorder from schizophrenia using <i>BDNF </i> haplotypes. British Journal of Psychiatry, 2009, 194, 313-318.	1.7	36
125	Screening embryos for polygenic conditions and traits: ethical considerations for an emerging technology. Genetics in Medicine, 2021, 23, 432-434.	1.1	36
126	Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 418-433.	0.7	35

#	Article	IF	Citations
127	Utility of polygenic embryo screening for disease depends on the selection strategy. ELife, 2021, 10, .	2.8	34
128	Expanded genetic screening panel for the Ashkenazi Jewish population. Genetics in Medicine, 2016, 18, 522-528.	1.1	33
129	Stress-Dependent Association Between Polygenic Risk for Schizophrenia and Schizotypal Traits in Young Army Recruits. Schizophrenia Bulletin, 2018, 44, 338-347.	2.3	33
130	DTNBP1 is associated with imaging phenotypes in schizophrenia. Human Brain Mapping, 2009, 30, 3783-3794.	1.9	32
131	Left middle temporal gyrus activation during a phonemic discrimination task. NeuroReport, 2004, 15, 389-393.	0.6	31
132	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. Psychoneuroendocrinology, 2016, 72, 1-10.	1.3	31
133	Multivariate genome-wide analysis of education, socioeconomic status and brain phenome. Nature Human Behaviour, 2021, 5, 482-496.	6.2	30
134	Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian Journal of Psychiatry, 2021, 62, 102732.	0.9	29
135	Genetic variation in the DAOA gene complex: Impact on susceptibility for schizophrenia and on cognitive performance. Schizophrenia Research, 2008, 103, 169-177.	1.1	28
136	Brain White Matter Development Is Associated with a Human-Specific Haplotype Increasing the Synthesis of Long Chain Fatty Acids. Journal of Neuroscience, 2014, 34, 6367-6376.	1.7	27
137	Coding and Noncoding Gene Expression Biomarkers in Mood Disorders and Schizophrenia. Disease Markers, 2013, 35, 11-21.	0.6	26
138	Age-Normative Pathways of Striatal ConnectivityÂRelated to Clinical Symptoms in the General Population. Biological Psychiatry, 2019, 85, 966-976.	0.7	26
139	Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test. Schizophrenia Research, 2006, 81, 157-166.	1.1	25
140	Independent evidence for an association between general cognitive ability and a genetic locus for educational attainment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 363-373.	1.1	25
141	The time and place of European admixture in Ashkenazi Jewish history. PLoS Genetics, 2017, 13, e1006644.	1.5	25
142	Increased stress and smaller anterior hippocampal volume. NeuroReport, 2006, 17, 1825-1828.	0.6	24
143	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Human Genetics, 2018, 137, 343-355.	1.8	24
144	Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia. Neuropsychopharmacology, 2021, 46, 1140-1144.	2.8	24

#	Article	IF	Citations
145	ECT-induced cognitive side effects are associated with hippocampal enlargement. Translational Psychiatry, 2021, 11, 516.	2.4	24
146	Structural similarity networks predict clinical outcome in early-phase psychosis. Neuropsychopharmacology, 2019, 44, 915-922.	2.8	23
147	COMT genotype and manic symptoms in schizophrenia. Schizophrenia Research, 2006, 87, 28-31.	1.1	22
148	A schizophrenia risk gene, ZNF804A, is associated with brain white matter microstructure. Schizophrenia Research, 2014, 155, 15-20.	1.1	22
149	Parasympathetic arousal-related cortical activity is associated with attention during cognitive task performance. Neurolmage, 2020, 208, 116469.	2.1	21
150	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. Neuron, 2021, 109, 1465-1478.e4.	3.8	21
151	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. Schizophrenia Research, 2014, 152, 365-372.	1.1	20
152	Excess of homozygosity in the major histocompatibility complex in schizophrenia. Human Molecular Genetics, 2014, 23, 6088-6095.	1.4	18
153	The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research, 2018, 195, 306-317.	1.1	17
154	Analysis of TBX1 Variation in Patients with Psychotic and Affective Disorders. Molecular Medicine, 2007, 13, 407-414.	1.9	16
155	Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis. Neuropsychopharmacology, 2019, 44, 1948-1954.	2.8	16
156	International Society of Psychiatric Genetics Ethics Committee: Issues facing us. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 543-554.	1.1	16
157	Neuroanatomical bases of electrodermal hypo-responding: A cluster analytic study. International Journal of Psychophysiology, 1996, 22, 141-153.	0.5	15
158	The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. Pharmacogenetics and Genomics, 2016, 26, 235-242.	0.7	15
159	Genome wide study of tardive dyskinesia in schizophrenia. Translational Psychiatry, 2021, 11, 351.	2.4	13
160	Schizotypal status as a developmental stage in studies of risk for schizophrenia., 1995,, 107-132.		13
161	ldentifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Neuropsychopharmacology, 2021, 46, 1788-1801.	2.8	12
162	Limited Evidence for Association of Genome-Wide Schizophrenia Risk Variants on Cortical Neuroimaging Phenotypes. Schizophrenia Bulletin, 2016, 42, 1027-1036.	2.3	11

#	Article	IF	Citations
163	Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging and Behavior, 2019, 13, 541-553.	1.1	11
164	Genetic architecture of prostate cancer in the Ashkenazi Jewish population. British Journal of Cancer, 2011, 105, 864-869.	2.9	10
165	Common variants of IRF3 conferring risk of schizophrenia. Journal of Psychiatric Research, 2015, 64, 67-73.	1.5	10
166	Neurodevelopmental processes in schizophrenia and schizotypal personality disorder., 1995,, 56-76.		9
167	Striatal functional connectivity in psychosis relapse: A hypothesis generating study. Schizophrenia Research, 2022, 243, 342-348.	1.1	9
168	Molecular Genetics of the Psychosis Phenotype. Canadian Journal of Psychiatry, 2012, 57, 446-453.	0.9	8
169	In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia. American Journal of Psychiatry, 2016, 173, 732-733.	4.0	8
170	Apolipoprotein E-ε4 allele predicts escalation of psychotic symptoms in late adulthood. Schizophrenia Research, 2019, 206, 82-88.	1.1	8
171	Brain Imaging Research on Electrodermal Activity in Humans. , 1993, , 115-135.		8
172	Cognitive deficits in schizophrenia: shortâ€ŧerm and longâ€ŧerm. World Psychiatry, 2008, 7, 29-30.	4.8	7
173	Length Distributions of Identity by Descent Reveal Fine-Scale Demographic History. American Journal of Human Genetics, 2012, 91, 1150.	2.6	7
174	Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort. Pharmacogenomics Journal, 2019, 19, 109-114.	0.9	7
175	The Timing of Neurodevelopmental Abnormality in Schizophrenia: An Integrative Review of the Neuroimaging Literature. CNS Spectrums, 2001, 6, 233-255.	0.7	6
176	The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. Schizophrenia Bulletin, 2012, 38, 1-4.	2.3	6
177	A Common Polymorphism in <i>SCN2A</i> Predicts General Cognitive Ability through Effects on PFC Physiology. Journal of Cognitive Neuroscience, 2015, 27, 1766-1774.	1.1	6
178	F10. DIFFERENTIAL EXPRESSION OF MICRORNAS IN CEREBROSPINAL FLUID AND PLASMA SAMPLES IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S221-S222.	2.3	6
179	Empirical Support for DSM-IV Schizoaffective Disorder: Clinical and Cognitive Validators from a Large Patient Sample. PLoS ONE, 2013, 8, e63734.	1.1	5
180	Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response. Schizophrenia Bulletin Open, 2020, 1, sgaa014.	0.9	5

#	Article	IF	Citations
181	Genomeâ€wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 511-519.	1.1	4
182	Leveraging correlations between variants in polygenic risk scores to detect heterogeneity in GWAS cohorts. PLoS Genetics, 2020, 16, e1009015.	1.5	4
183	Genome-wide linkage scan of major depressive disorder in two Dagestan genetic isolates. Open Medicine (Poland), 2011, 6, 616-624.	0.6	3
184	Multi-Trait Analysis of GWAS and Biological Insights Into Cognition: A Response to Hill (2018). Twin Research and Human Genetics, 2018, 21, 394-397.	0.3	3
185	Treatment of the Schizophrenia Prodrome. , 2004, , 303-323.		2
186	Contributions of parasympathetic arousal-related activity to cognitive performance in First Episode Psychosis patients and controls. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, , .	1.1	2
187	Capacities and Limitations of Using Polygenic Risk Scores for Reproductive Decision Making. American Journal of Bioethics, 2022, 22, 42-45.	0.5	2
188	97. The hillside RAPP clinic: why the sudden interest in the schizophrenia prodrome?. Biological Psychiatry, 2000, 47, S29-S30.	0.7	1
189	330. Atypical antipsychotic effects on fMRI in drug-naive schizophrenia. Biological Psychiatry, 2000, 47, S99.	0.7	1
190	Applications of temporal kernel canonical correlation analysis in adherence studies. Statistical Methods in Medical Research, 2017, 26, 2437-2454.	0.7	1
191	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene, 2018, 16, 143-164.	0.3	1
192	F148. 301 Cognitive Loci Identified in Large-Scale GWAS Meta-Analysis. Biological Psychiatry, 2019, 85, S270.	0.7	1
193	The effects of lorazepam on cortico-striatal connectivity in schizophrenia. Schizophrenia Research, 2020, 223, 363-365.	1.1	1
194	Pharmacogenomics Applications in Psychiatric Disorders. Methods in Pharmacology and Toxicology, 2008, , 369-394.	0.1	1
195	MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia. Schizophrenia Research, 1997, 24, 151.	1.1	0
196	Parcellation of the frontal lobes in first-episode schizophrenia. Schizophrenia Research, 1997, 24, 158.	1.1	0
197	93. Behavioral profiles of adolescents putatively prodromal for schizophrenia. Biological Psychiatry, 2000, 47, S28.	0.7	0
198	94. Neuropsychological correlates of mesiotemporal volumes in schizophrenia. Biological Psychiatry, 2000, 47, S28-S29.	0.7	0

#	Article	IF	CITATIONS
199	95. Smooth pursuit eye movement dysfunction in patients at clinical risk for schizophrenia. Biological Psychiatry, 2000, 47, S29.	0.7	0
200	98. A self-report questionnaire to screen for prodromal schizophrenia. Biological Psychiatry, 2000, 47, S30.	0.7	0
201	Molecular Genetics of the Psychosis Phenotype. Canadian Journal of Psychiatry, 2012, 57, 1-8.	0.9	0
202	349. Neuroimaging Biomarkers of ECT Response. Biological Psychiatry, 2017, 81, S143.	0.7	0
203	F198. Parahippocampal Thickness Predicts Treatment Improvement in Early and Chronic Schizophrenia. Biological Psychiatry, 2018, 83, S315-S316.	0.7	0
204	S20. PARAHIPPOCAMPAL THICKNESS PREDICTS TREATMENT IMPROVEMENT IN EARLY AND CHRONIC SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S330-S331.	2.3	0
205	O31. Age-Normative Pathways of Striatal Connectivity Relate to ADHD Symptoms in the General Population. Biological Psychiatry, 2018, 83, S121.	0.7	0
206	195. Fatty Acid Bioavailability and Membrane Dynamics are Associated With White Matter Integrity and Neurocognitive Performance During Development. Biological Psychiatry, 2018, 83, S78-S79.	0.7	0
207	T228. Identifying Key SNPs and Pathways Underlying Cognition, Education and Schizophrenia. Biological Psychiatry, 2018, 83, S217.	0.7	0
208	LARGE-SCALE GWAS META-ANALYSIS AND MULTI-TRAIT ANALYSIS YIELDS DOZENS OF NOVEL LOCI AND NOVEL GENETIC CORRELATES FOR GENERAL COGNITIVE ABILITY. European Neuropsychopharmacology, 2019, 29, 8808-S809.	0.3	0
209	T175. The Effects of Lorazepam on Resting-State Functional Connectivity. Biological Psychiatry, 2019, 85, S197.	0.7	0
210	92 NOVEL ULTRA-RARE EXONIC VARIANTS IDENTIFIED IN A FOUNDER POPULATION IMPLICATE CADHERINS, PROTOCADHERINS, AND AUTISM/ID GENES IN SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S111.	0.3	0
211	46USING PLEIOTROPY TO DISSECT FUNCTIONAL PATHWAYS IN COGNITION, EDUCATION, AND SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S1093.	0.3	0
212	SA51THE LIMITS OF POLYGENIC EMBRYO SELECTION FOR COGNITIVE ABILITY. European Neuropsychopharmacology, 2019, 29, S1215-S1216.	0.3	0
213	O10.8. STRIATAL CONNECTIVITY IN BREAKTHROUGH PSYCHOSIS ON ANTIPSYCHOTIC MAINTENANCE: PRELIMINARY RESULTS FROM THE BAMM STUDY. Schizophrenia Bulletin, 2019, 45, S193-S193.	2.3	0
214	O35. Relationship of Rich Club Organization and MCCB Reasoning Domain in First Episode Schizophrenia. Biological Psychiatry, 2019, 85, S120.	0.7	0
215	SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS. European Neuropsychopharmacology, 2019, 29, S999.	0.3	0
216	M41 IDENTIFYING NOOTROPIC DRUG TARGETS VIA LARGE-SCALE COGNITIVE GWAS AND TRANSCRIPTOMICS. European Neuropsychopharmacology, 2019, 29, S187-S188.	0.3	0

#	Article	IF	Citations
217	Title is missing!. , 2020, 16, e1009015.		О
218	Title is missing!. , 2020, 16, e1009015.		0
219	Title is missing!. , 2020, 16, e1009015.		O
220	Title is missing!. , 2020, 16, e1009015.		0
221	Title is missing!. , 2020, 16, e1009015.		O
222	Title is missing!. , 2020, 16, e1009015.		0